Human SU-DHL-5 and TMD-8 B-lymphome cell line subclones
Ontology highlight
ABSTRACT:
PROVIDER: PRJEB14876 | ENA |
REPOSITORIES: ENA
Dataset's files
| Action | DRS | |||
|---|---|---|---|---|
| ERR1544600_1.fastq.gz | Fastqsanger.gz | |||
| ERR1544600_2.fastq.gz | Fastqsanger.gz | |||
| ERR1544601_1.fastq.gz | Fastqsanger.gz | |||
| ERR1544601_2.fastq.gz | Fastqsanger.gz | |||
| ERR1544602_1.fastq.gz | Fastqsanger.gz |
Items per page: 5 1 - 5 of 10 |
Similar Datasets
Project description:Genetic heterogeneity though common in tumors has been rarely documented in cell lines. To examine how often B-lymphoma cell lines are comprised of subclones, we performed immunoglobulin (Ig) heavy chain hypermutation analysis. Revealing that subclones are not rare in B-cell lymphoma cell lines, 6/49 Ig hypermutated cell lines (12%) consisted of subclones with individual Ig mutations. Subclones were also identified in 2/284 leukemia/lymphoma cell lines exhibiting bimodal CD marker expression. We successfully isolated 10 subclones from four cell lines HG3, SU-DHL-5, TMD-8, U-2932). Whole exome sequencing was performed to molecularly characterize these subclones. We in detail describe the clonal structure of cell line HG3, derived from chronic lymphocytic leukemia. HG3 consists of three lineages each bearing clone-specific aberrations, gene expression and DNA methylation patterns. While donor patient leukemic cells were CD5+, two of three HG3 subclones had independently lost this marker. CD5 on HG3 cells was regulated by epigenetic/transcriptional mechanisms rather than by alternative splicing as reported hitherto. In conclusion, we show that the presence of subclones in cell lines carrying individual mutations and characterized by sets of differentially expressed genes is not uncommon. We show also that these subclones can be useful isogenic models for regulatory and functional studies.
2016-09-30 | E-MTAB-4956 | biostudies-arrayexpress
Project description:SU-DHL-5 cells display limited expression of the SUMO isopeptidase SENP6. In this experiment, the chromatin associated fraction of SU-DHL-5 cells was analysed by mass spectrometry. SU-DHL-5 cells were either stably transfected with an empty vector or with a SENP6 expression construct. Changes in protein levels were compared between these two cell lines in triplicate experiments.
2022-02-17 | PXD027355 | Pride
Project description:To further figure out the molecular mechanisms of IL-17A-mediated DLBCL cells growth, we used the Whole Human Genome Oligo Microarray (4×44K, Agilent Technologies) to identify genes expression. Six samples of SU-DHL-2 cells (2×10^6 cells/ml) co-cultured with or without IL-17A (200pg/ml) for 72hr in vivo. Three samples of SU-DHL-2 cells were all co-cultured with IL-17A , other three samples of SU-DHL-2 cells without IL-17A treatment were used as controls. Then, all these six samples of SU-DHL-2 cells were measured by microarray.
2018-06-16 | GSE115855 | GEO
Project description:RAD21 ChIA-PET in human SU-DHL-4 cells For data usage terms and conditions, please refer to http://www.genome.gov/27528022 and http://www.genome.gov/Pages/Research/ENCODE/ENCODE_Data_Use_Policy_for_External_Users_03-07-14.pdf
2019-03-03 | GSE127039 | GEO
Project description:RAD21 ChIA-PET in human SU-DHL-2 cells For data usage terms and conditions, please refer to http://www.genome.gov/27528022 and http://www.genome.gov/Pages/Research/ENCODE/ENCODE_Data_Use_Policy_for_External_Users_03-07-14.pdf
2019-03-03 | GSE127019 | GEO
Project description:Genetic heterogeneity though common in tumors has been rarely documented in cell lines. To examine how often B-lymphoma cell lines are comprised of subclones, we performed immunoglobulin (Ig) heavy chain hypermutation analysis. Revealing that subclones are not rare in B-cell lymphoma cell lines, 6/49 Ig hypermutated cell lines (12%) consisted of subclones with individual Ig mutations. Subclones were also identified in 2/284 leukemia/lymphoma cell lines exhibiting bimodal CD marker expression. We successfully isolated 10 subclones from four cell lines HG3, SU-DHL-5, TMD-8, U-2932). Whole exome sequencing was performed to molecularly characterize these subclones. We in detail describe the clonal structure of cell line HG3, derived from chronic lymphocytic leukemia. HG3 consists of three lineages each bearing clone-specific aberrations, gene expression and DNA methylation patterns. While donor patient leukemic cells were CD5+ , two of three HG3 subclones had independently lost this marker. CD5 on HG3 cells was regulated by epigenetic/transcriptional mechanisms rather than by alternative splicing as reported hitherto. In conclusion, we show that the presence of subclones in cell lines carrying individual mutations and characterized by sets of differentially expressed genes is not uncommon. We show also that these subclones can be useful isogenic models for regulatory and functional studies.
2016-09-30 | E-MTAB-4955 | biostudies-arrayexpress
Project description:To understand the mechanisms of CBL0137 in B-NHL therapy, gene expression changes of SU-DHL-4, Raji and Jeko cell lines after CBL0137 treatment were analyzed by RNA-seq
2023-02-07 | GSE208679 | GEO
Project description:Genes expression of SU-DHL-2 cells treated with IL-17A
| PRJNA476315 | ENA
Project description:Global protein profiling and global phospho-protein profiling in human diffuse large B cell lymphoma cell line SU-DHL-4 treated with Rapamycin at two time points compared with DMSO control was performed by Poochon Scientific using the TMT-18plex labeling based quantitative proteomics method and liquid chromatography-tandem mass spectrometry (LC-MS/MS). Nine frozen cell pellet samples (6 million cells each) were received and processed for the study by Poochon Scientific. The preparation of the protein lysates from 9 frozen pellet samples was performed according to the method described in method section. Protein concentrations were measured using the BCA method. An equal amount of total protein from each sample was processed for MS analysis. In summary, 200 µg of protein from each of the 9 samples was processed for trypsin digestion, followed by TMT-multiplex labeling using one TMT-18plex sets. 10 unique TMT tags were used to label 150 µg of trypsin-digested peptides from each of the 9 digests and one master mixture (an equal amount mixture of 9 digests) (Table 1). After fractionation by UHPLC, 90% of the labeled peptides fractions (6 fractions) was used for enrichment of phospho-peptides, and 10% of the fractions (12 fractions) were analyzed by 12x 110 min LC/MS/MS runs. 10 unique TMT tags from the TMT-18plex set were used to label 9 trypsin-digested peptides plus one master mixture (Table 1). Table 1: Description (Label, BCA (mg/ml), TMT-tag); DMSO rep1 (DMSO1, 4.3 mg/ml, 126);DMSO rep2 (DMSO2, 4.12 mg/ml, 127N);DMSO rep3 (DMSO3, 4.5 mg/ml, 127C);Rapamycin 24h rep1 (Rapamycin24h1, 3.32 mg/ml, 128N);Rapamycin 24h rep2 (Rapamycin24h2, 4.62 mg/ml, 128C);Rapamycin 24h rep3 (Rapamycin24h3, 3.18 mg/ml, 129N);Rapamycin 48h rep1 (Rapamycin48h1, 3.46 mg/ml, 129C);Rapamycin 48h rep2 (Rapamycin48h2, 3.24 mg/ml, 130N);Rapamycin 48h rep3 (Rapamycin48h3, 3.68 mg/ml, 130C);Master mix mix of equal amount of 9 samples (131N). After TMT labeling, the 10 labeled peptides were mixed followed by two fractionations using basic reversed-phase UHPLC. 12 fractions from 10% aliquot were generated and analyzed sequentially by 12x 110-minute LC-MS/MS runs. 12 fractions from 90% aliquot were combined into 6 fractions and then phospho-peptides were enriched by using ThermoFisher TiO2 Phosphopeptide Enrichment Kit and analyzed sequentially by 6x 110-minute LC-MS/MS runs.
2025-09-03 | PXD067812 | Pride
Project description:Gene expression in SU-DIPG20, SU-DIPG31, SU-DIPG35, and SU-DIPG-48 primary human tumor samples
| PRJNA927324 | ENA